Drug intelligence / Profile preview

Yushen Tongluo Granule

Development stage: Preclinical
Lead developer: Shanghai General Hospital
Administration: Oral

Overview

Yushen Tongluo Granule (YSTLG) is a Traditional Chinese Medicine (TCM) in granule form, currently under investigation for its potential in treating anovulatory infertility. Clinical trials have explored its efficacy and safety when combined with clomiphene citrate, demonstrating its ability to improve ovulation rates and endometrial thickness. While the precise molecular mechanism remains to be fully elucidated, it is hypothesized that YSTLG may exert its therapeutic effects by increasing estrogen levels or promoting endometrial angiogenesis.

Other names: yushentongluo育肾通络颗粒

Beyond the preview

Go deeper on Yushen Tongluo Granule.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yushen Tongluo Granule.

Explore the full profile